PALYNZIQ
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 31 Dec 2024)
What this means for you
Registered since 02 Oct 2018. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 02 Oct 2028: the §8 & §9 renewal).
Record
- Serial number
- 87516640
- Registration number
- 5576853
- Mark type
- Stylized text
- Filed
- 05 Jul 2017
- Published for opposition
- 07 Nov 2017
- Registered
- 02 Oct 2018
- Next maintenance filing
- §8 & §9 renewal, due by 02 Oct 2028 (grace period to 02 Apr 2029)
- Attorney of record
- Gregory J. Chinlund
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of genetic diseases and disorders; Pharmaceutical preparations for use in enzyme therapy
Owner
- Biomarin Pharmaceutical Inc., Novato, CA, US
- Biomarin Pharmaceutical Inc., Novato, CA, US
- Biomarin Pharmaceutical Inc., Novato, CA, US
Board proceedings on this mark
The owner also pleads this mark in 1 other Board proceeding.
Prosecution history
- 31 Dec 2024 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 31 Dec 2024 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 30 Dec 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 30 Jul 2024 — TEAS SECTION 8 & 15 RECEIVED
- 02 Oct 2023 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 09 Dec 2020 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 09 Dec 2020 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 09 Dec 2020 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 09 Dec 2020 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 02 Oct 2018 — REGISTERED-PRINCIPAL REGISTER
- 29 Aug 2018 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 28 Aug 2018 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 21 Aug 2018 — STATEMENT OF USE PROCESSING COMPLETE
- 23 Jul 2018 — USE AMENDMENT FILED
- 20 Aug 2018 — CASE ASSIGNED TO INTENT TO USE PARALEGAL